PANews reported on October 16th that digital asset finance company Propanc Biopharma announced a strategic financing agreement with family office Hexstone Capital for up to $100 million. The financing will accelerate the biopharmaceutical company's clinical pipeline development and aims to grow its digital asset portfolio to $100 million or more within the next 12 months. Hexstone Capital has previously invested in several companies with digital asset portfolios, including BTC, ETH, SOL, and DOGE.
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact
crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.